{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T19:20:28Z","timestamp":1771701628290,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["GXWD20201231165807007-20200811141635001"],"award-info":[{"award-number":["GXWD20201231165807007-20200811141635001"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["GXWD20201231165807007-20200811151825001"],"award-info":[{"award-number":["GXWD20201231165807007-20200811151825001"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20200109120408264"],"award-info":[{"award-number":["JCYJ20200109120408264"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017607","name":"Shenzhen Fundamental Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077009"],"award-info":[{"award-number":["22077009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bbrc.2023.05.025","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T11:06:10Z","timestamp":1683543970000},"page":"115-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy"],"prefix":"10.1016","volume":"666","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6844-930X","authenticated-orcid":false,"given":"Ziang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8244-734X","authenticated-orcid":false,"given":"Nannan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinkai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-6130","authenticated-orcid":false,"given":"Junmin","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2023.05.025_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102241","article-title":"Emerging strategies for treating gout","volume":"65","author":"Huddleston","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4081\/reumatismo.2011.238","article-title":"Clinical features of gout","volume":"63","author":"Grassi","year":"2012","journal-title":"Reumatismo"},{"key":"10.1016\/j.bbrc.2023.05.025_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nri2725","article-title":"NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?","volume":"10","author":"Tschopp","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.bbrc.2023.05.025_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.140458","article-title":"The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors","volume":"92","author":"Wechalekar","year":"2014","journal-title":"J.\u00a0Rheumatol. Suppl."},{"issue":"2017","key":"10.1016\/j.bbrc.2023.05.025_bib7","first-page":"29","article-title":"Updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrc.2023.05.025_bib8","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","article-title":"Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases","volume":"15","author":"Ottaviani","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbrc.2023.05.025_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrrheum.2014.6","article-title":"Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE","volume":"10","author":"Deane","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.925219","article-title":"Review of urate-lowering therapeutics: from the past to the future","volume":"13","author":"Jenkins","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2012-202594","article-title":"Gout treatment: should we aim for rapid crystal dissolution?","volume":"72","author":"Pascual","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrc.2023.05.025_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1107\/S0907444908013590","article-title":"Structures of Arthrobacter globiformis urate oxidase-ligand complexes","volume":"D64","author":"Juan","year":"2008","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bbrc.2023.05.025_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2021.105978","article-title":"Soluble expression of bioactive recombinant porcine-human chimeric uricase mutant employing MBP-SUMO fusion system","volume":"189","author":"Zhou","year":"2022","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.bbrc.2023.05.025_bib14","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1073\/pnas.1320393111","article-title":"Evolutionary history and metabolic insights of ancient mammalian uricases","volume":"111","author":"Kratzer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2023.05.025_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/2042098617727714","article-title":"Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations","volume":"8","author":"Guttmann","year":"2017","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.bbrc.2023.05.025_bib16","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41401-019-0269-x","article-title":"Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy","volume":"40","author":"Shi","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2023.05.025_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167935","article-title":"A\u00a0therapeutic uricase with reduced immunogenicity risk and improved development properties","volume":"11","author":"Nyborg","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2023.05.025_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173650","article-title":"Albumin-binding domain extends half-life of glucagon-like peptide-1","volume":"890","author":"Tan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbapap.2005.10.005","article-title":"G148-GA3: a streptococcal virulence module with atypical thermodynamics of folding optimally binds human serum albumin at physiological temperatures","volume":"1753","author":"Rozak","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2023.05.025_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174152","article-title":"Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain","volume":"904","author":"Zhang","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.vaccine.2004.05.022","article-title":"Short peptide sequences containing MHC class I and\/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice","volume":"23","author":"Fifis","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.bbrc.2023.05.025_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1476-5381.2010.01068.x","article-title":"Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [(1)(8)F]-IL1RA and PET imaging in rats","volume":"162","author":"Cawthorne","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","article-title":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review","volume":"51","author":"Keenan","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bbrc.2023.05.025_bib24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A\u00a0randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bbrc.2023.05.025_bib25","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrc.2023.05.025_bib26","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann. Rheum. Dis."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23005818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23005818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:30:18Z","timestamp":1757766618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23005818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"alternative-id":["S0006291X23005818"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.05.025","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}